Company / Cash & Equivalents
MBX Biosciences, Inc. Cash & Equivalents History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$49.4M
FY2024
5-year range
$30.5M / $49.4M
FY2023-FY2024
Trend
+61.7%
vs FY2023
Sector context
#184 of 207
Health Care
What the data says
MBX Biosciences, Inc.'s cash & equivalents of $49M is lower than 89% of companies in the Health Care sector (FY2024).
Based on SEC 10-K filings.
$49M in FY2024.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 11% in Health CareTop 89% of 207This company $49.4M Sector average $669.5M
▼
-92.6% below sector average
Key checks
Key Insights
- In FY2024, cash & equivalents increased 61.7% year-over-year.
- Ranks #184 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 9.64 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $49.4M | +61.7% |
| FY2023 | $30.5M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026